Uplizna (inebilizumab or inebilizumab-cdon) is FDA-approved to treat certain adults with a nerve condition that affects the eye and spinal cord called neuromyelitis optica spectrum disorder (NMOSD). This medication is a CD19-directed monoclonal antibody that's given as an infusion through the vein by a healthcare provider. It's given only twice a year after the first couple doses, but has side effects like joint pain, headache, and infusion reactions.
Uplizna (inebilizumab) is an anti-CD19 monoclonal antibody. It's unclear how the medication works, but it's thought to attach to CD19 proteins that are found on your B cells (a type of immune cell that plays a role in inflammation).
Once attached, the medication destroys these B cells and lowers the amount of B cells in the body. This might help treat NMOSD, a condition that happens when the immune system attacks the nerves of the eye and spinal cord and causes swelling.
The following side effects may get better over time as your body gets used to the medication. Let your healthcare provider know immediately if you continue to experience these symptoms or if they worsen over time.
Contact your healthcare provider immediately if you experience any of the following.
Side effects that you should report to your care team as soon as possible:
Side effects that usually do not require medical attention (report these to your care team if they continue or are bothersome):
Yes. The FDA approved Uplizna (inebilizumab) and designated the medication as an "orphan drug" for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in certain adults. Orphan drugs are medications that are used to treat rare medical conditions, such as NMOSD.
Yes, Uplizna (inebilizumab) is considered a biologic. This means that the medication is made in the lab from living sources. Uplizna (inebilizumab) is a monoclonal antibody (a type of protein) that attaches to specific white blood cells that play a role in causing inflammation in the body. The medication then destroys these white blood cells, which might help lower inflammation in the nerves of the eye and spinal cord.
Your provider will prescribe you "pre-treatment" medications to take before Uplizna (inebilizumab) infusions to lower your risk for and the severity of infusion reactions. These medications can include antihistamines and fever-reducers, such as acetaminophen (Tylenol). Take these medications 30 to 60 minutes before your infusion. At the clinic, your care team will give you a corticosteroid as an injection through the vein 30 minutes before your Uplizna (inebilizumab) infusion.
Each Uplizna (inebilizumab) infusion takes about an hour and a half. Keep in mind that your care team will watch you during your treatment and at least one hour after your infusion is complete in case you have an infusion reaction. It's a good idea to be prepared for your appointment by bringing something to do (e.g., electronic device, book), a light snack, and water. Speak with your provider about how to best prepare for your appointments.
Let your provider know about all your current medications before you start Uplizna (inebilizumab). Taking Uplizna (inebilizumab) together with medications that weaken your immune system can raise your risk of infections. Discuss with your provider about whether Uplizna (inebilizumab) is the right treatment for you with your other medications.
Ask your provider or pharmacist whether you can get a specific vaccine while you're taking Uplizna (inebilizumab). Your providers can check whether you can get the vaccine. Certain vaccines called live vaccines aren't recommended for you if you're currently taking Uplizna (inebilizumab) because the medication might affect how your body responds to them. Examples of live vaccines include Varivax (varicella vaccine) for chickenpox and MMR (measles, mumps, and rubella vaccine). For this reason, it's best to be up to date on all your vaccinations before you start Uplizna (inebilizumab) and to get any that you need a month before your first infusion.
Speak to your provider before you start your treatment with Uplizna (inebilizumab) if you're breastfeeding or planning to breastfeed. It's not known whether the medication can pass into your breast milk and harm your baby. Discuss with your provider about the safest way to feed your baby while you're getting Uplizna (inebilizumab) infusions.
Uplizna (inebilizumab) and Soliris (eculizumab) are both monoclonal antibodies that can treat certain adults with neuromyelitis optica spectrum disorder (NMOSD). They're both given as an infusion into the vein by a healthcare provider, but Uplizna is given less often than Soliris. You only need to get Uplizna infusions twice a year after the first few doses. But you need to get Soliris infusions every week for the first several doses, then every other week. In addition, both medications can raise the risk for infections, but Soliris has a particular risk for meningococcal infection and requires specific vaccination against it before you start treatment. Discuss with your provider about which medication is right for you.
Uplizna (inebilizumab) can cause some serious health issues. This risk may be even higher for certain groups. If this worries you, talk to your doctor or pharmacist about other options.
Uplizna (inebilizumab) can cause infusion reactions, such as headache, nausea, sleepiness, trouble breathing, fever, muscle pain, and rash. These reactions can happen during any of your Uplizna (inebilizumab) infusions, but are more common with the first infusion.
Your provider will prescribe medications, such as corticosteroids, antihistamines, and fever-reducers, for you to take before your infusion to lower the risk or seriousness of these infusion reactions. Your care team will also watch for reactions during the infusion and for at least an hour after the infusion. Let your nurse know if you have any reactions during your infusion. Your provider can temporarily stop the infusion, slow it down, or give you appropriate treatment.
Uplizna (inebilizumab) can lower your immune system and put you at risk for infections. The most common types of infections reported in clinical studies include urinary tract infections (UTIs), the common cold, and flu. In addition, this medication can potentially make hepatitis B infection or tuberculosis (TB) worse or come back. Although rare, Uplizna (inebilizumab) might also raise the risk of a serious brain infection called progressive multifocal leukoencephalopathy (PML).
Before you start Uplizna (inebilizumab), tell your provider about your medical history. Your provider will examine you for hepatitis B because you might not be able to take this medication if you're currently infected. Your provider will also check for TB to see whether you need additional antibiotics to prevent it from getting worse or coming back. Tell your provider if you currently have an infection because it should be treated before you get your infusions.
Let your provider know right away if you have signs and symptoms of an infection, such as fever, chills, muscle aches, constant cough, sore throat, skin redness or swelling, diarrhea, or burning feeling during urination. Also tell your provider right away if you have any signs of PML, including weakness on one side of the body, loss of coordination in your arms or legs, vision changes, changes in thinking or memory, confusion, or changes in personality.
Long-term treatment with Uplizna (inebilizumab) can lower the amount of antibodies called immunoglobulins in your body. These antibodies are made by your white blood cells to help your body fight off infections. Your provider will check your immunoglobulin levels during treatment. Your provider might stop your Uplizna (inebilizumab) treatment if your levels get too low.
Uplizna (inebilizumab) might cause harm to your unborn baby if you take it during pregnancy. If you can become pregnant, you should use birth control during Uplizna (inebilizumab) treatment and for at least 6 months after your last dose.
The typical dose is 300 mg given as an infusion into the vein (intravenously or IV). The first two doses are given 2 weeks apart. After that, you'll get the 300 mg IV infusion every 6 months.
Contraindications are specific health conditions or situations in which a person should not take a medication due to safety concerns. If you have any of the following conditions or if any of the following apply to you, let your healthcare provider know because Uplizna (inebilizumab) will not be safe for you to take.